ArticlePLoS pathogens2026
Emergence of a novel GII.17 variant is associated with immune evasion rather than an altered HBGA-binding profile.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The epidemiology of noroviruses, a major cause of gastroenteritis in humans, is shaped by their continuous evolution. Novel genotypes and variants periodically emerge, replacing previously dominant strains. In 2024, a novel GII.17 variant led to an increased number of notified outbreaks, becoming the dominant genotype detected in Europe. To investigate if this surge in GII.17 detection is attributable to changes in the binding and antigenicity of this novel variant, we compared properties of a GII.17 2024 strain with representative GII.17 strains from 2005 (Clade B), 2014 (Clade C), and 2015 (Clade D), and the epidemic GII.4 Sydney 2012 variant. Norovirus virus-like particles (VLPs) were used to assess binding to saliva samples and human intestinal tissues with different histo-blood group antigen (HBGA) profiles. Binding specificity to individual glycans was determined using synthetic HBGAs. Additionally, VP1-NanoLuc (NLuc) fusion proteins were used in binding blocking assays to evaluate the antigenic properties of the variants using 75 sera from healthy adults that were collected during different time periods of GII.17 circulation (the winters of 2009-2010, 2015 and 2024). Compared with other GII.17 variants, the 2024 strain exhibited amino acid substitutions in the P2 domain, which contains both antigenic sites and the HBGA binding site. Binding-blocking assays with human sera confirmed that the 2024 variant is antigenically distinct from the 2005 and 2015 GII.17 strains but closely related to the 2014 variant. All post-2005 GII.17 strains showed a broader HBGA binding profile compared to the GII.17 2005 strain, likely contributing to their more successful spread. These findings show that the recent re-emergence of GII.17 coincided with antigenic drift, enabling it to escape from pre-existing immunity, but not with major changes in HBGA binding specificity. Understanding the factors influencing norovirus emergence is essential for the development of preventive strategies against future norovirus epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.